Background
Results
Patient, disease, and transplant characteristics
Other gender combination (n = 421) | Female UCB to male recipient (n = 131) | Pvaluea
| |
---|---|---|---|
Median patient age, years (range) | 43 (18–70) | 42 (18–67) | 0.48 |
Median year of SCT, years (range) | 2009 (2000–2013) | 2009 (2000–2013) | 0.24 |
Recipient M donor F, # (%) | 0 (0) | 131 (100) | / |
Recipient M donor M, # (%) | 119 (28) | 0 (0) | |
Recipient F donor F, # (%) | 157 (37) | 0 (0) | |
Recipient F donor M, # (%) | 145 (34) | 0 (0) | |
Median time from diagn to SCT, days | 210 | 231 | 0.48 |
Secondary AML, # (%) | 72 (17) | 18 (14) | 0.36 |
Status at transplantation, # (%) | |||
CR1 | 233 (55) | 59 (45) | 0.12 |
CR2+ | 92 (22) | 36 (27) | |
Advanced | 96 (23) | 36 (27) | |
Cytogenetics, # (%) | |||
Good riskb
| 17 (9) | 14 (21) | 0.005 |
Intermediate riskc
| 56 (29) | 26 (39) | |
High riskd
| 47 (25) | 8 (12) | |
Not reported/failed | 229 | 65 | |
Secondary AML | 72 (37) | 18 (27) | |
Recipient CMV-seronegative, # (%) | 100 (28) | 26 (27) | 0.83 |
Conditioning regimen, # (%) | |||
Myeloablative | 271 (65) | 94 (76) | 0.03 |
Reduced-intensity | 145 (35) | 30 (24) | |
ATG, # (%) | 232 (61) | 65 (56) | |
TNC at infusion ×107/kg | |||
Median (range) | 2.8 (0.33–40.3) | 2.5 (0.4–6.10) | 0.01 |
Missing data (# of patients) | 71 | 19 | |
Number of HLA disparities, # (%) | |||
0–1 mismatch | 121 (36) | 35 (33) | |
2–3 mismatches | 213 (64) | 70 (67) | 0.59 |
Missing data | 87 | 26 | |
Postgrafting immunosuppression, # (%) | |||
CSP alone | 140 (33) | 51 (39) | 0.19 |
CSP + MMF | 215 (51) | 55 (42) | |
Other/missing | 66 (16) | 25 (19) | |
Acute GVHD, # (%) | |||
Grades I–IV | 171 (43) | 59 (49) | 0.28 |
Grades II–IV | 99 (25) | 40 (33) | 0.08 |
Grades III–IV | 43 (11) | 18 (15) | 0.23 |
CI chronic GVHD @ 2 years, % | 28 | 21 | 0.44 |
Death from GVHD, # (%) | 29 (7) | 10 (8) | 0.77 |
Engraftment
GVHD
RI | NRM | LFS | OS | cGVHD | |
---|---|---|---|---|---|
Male to male | 22.8 % (15.4–31.1) | 36.6 % (28.1–45.1) | 40.7 % (31.3–50) | 42.4 % (32.8–52) | 15.7 % (8.3–25.2) |
Female to male | 29.2 % (21.1–37.8) | 40.8 % (32.3–49.2) | 29.9 % (21.3–38.6) | 33 % (24.1–41.9) | 10.1 % (4.7–18) |
Male to female | 29 % (21–37.5) | 35.1 % (26.7–43.6) | 35.9 % (27.1–44.7) | 40.9 % (32.1–49.8) | 13 % (6.9–21.1) |
Female to female | 26.3 % (18.9–34.2) | 28.4 % (20.4–36.9) | 45.3 % (36.5–54.1) | 51 % (42.3–59.7) | 11.6 % (6.1–19) |
P
| 0.8096 | 0.098598 | 0.040965 | 0.030146 | 0.83169 |
Logistic regression |
P
| OR | 95 % CI | ||
AGVH II+ | Female to male | 0.07 | 1.7 | 1.0 | 3.0 |
Age (years) | 0.60 | 1.0 | 1.0 | 1.0 | |
Status at Tx | |||||
CR1 versus CR2 | 0.07 | 0.6 | 0.3 | 1.0 | |
CR1 versus advanced
|
0.04
|
0.5
|
0.2
|
1.0
| |
ATG
|
0.02
|
0.5
|
0.3
|
0.9
| |
RIC | 0.20 | 1.5 | 0.8 | 2.9 | |
Sec AML | 0.59 | 0.8 | 0.4 | 1.7 | |
Infused cells >2.7 (median) | 0.25 | 0.7 | 0.5 | 1.2 | |
Nr mism >1 | 0.70 | 1.1 | 0.7 | 1.8 | |
AGVH III–IV | Female to male | 0.06 | 2.0 | 1.0 | 3.9 |
Age (years) | 0.90 | 1.0 | 1.0 | 1.0 | |
Status at Tx | |||||
CR1 versus CR2 | 0.38 | 0.7 | 0.3 | 1.5 | |
CR1 versus advanced
|
0.05
|
0.4
|
0.1
|
1.0
| |
ATG
|
0.03
|
0.5
|
0.2
|
0.9
| |
RIC | 0.80 | 1.1 | 0.5 | 2.6 | |
Sec AML | 0.56 | 1.3 | 0.6 | 3.0 | |
Infused cells >2.7 (median) | 0.99 | 1.0 | 0.5 | 1.9 | |
Nr mism >1 | 0.84 | 0.9 | 0.5 | 1.8 | |
Cox models |
P
| HR | 95 % CI | ||
NRM | Female to male | 0.06 | 1.5 | 1.0 | 2.2 |
Age (years) | 0.21 | 1.0 | 1.0 | 1.0 | |
Status at Tx | |||||
CR1 versus CR2
|
0.01
|
0.5
|
0.3
|
0.8
| |
CR1 versus advanced | 0.62 | 0.9 | 0.5 | 1.5 | |
ATG
|
0.04
|
1.5
|
1.0
|
2.4
| |
RIC | 0.09 | 0.6 | 0.4 | 1.1 | |
Sec AML | 0.06 | 1.6 | 1.0 | 2.4 | |
Infused cells >2.7 (median) | 0.18 | 0.8 | 0.5 | 1.1 | |
Nr mism >1 | 0.18 | 0.8 | 0.5 | 1.1 | |
RI | Female to male | 0.40 | 1.2 | 0.8 | 1.9 |
Age (years) |
0.03
|
1.0
|
1.0
|
1.0
| |
Status at Tx | |||||
CR1 versus CR2
|
<10–4
|
0.2
|
0.1
|
0.4
| |
CR1 versus advanced
|
<10–4
|
0.3
|
0.2
|
0.5
| |
ATG | 0.88 | 1.0 | 0.6 | 1.5 | |
RIC
|
0.04
|
1.7
|
1.0
|
2.9
| |
sec AML
|
0.00
|
0.2
|
0.1
|
0.4
| |
Infused cells > 2.7 (median) | 0.06 | 0.7 | 0.5 | 1.0 | |
Nr mism > 1 | 0.64 | 0.9 | 0.6 | 1.4 | |
LFS |
Female to male
|
0.04
|
1.4
|
1.0
|
1.9
|
Age (years)
|
0.03
|
1.0
|
1.0
|
1.0
| |
Status at Tx
| |||||
CR1 versus CR2
|
<10–4
|
0.4
|
0.3
|
0.5
| |
CR1 versus advanced
|
0.01
|
0.6
|
0.4
|
0.9
| |
ATG | 0.14 | 1.3 | 0.9 | 1.7 | |
RIC | 0.90 | 1.0 | 0.7 | 1.5 | |
Sec AML | 0.17 | 0.8 | 0.5 | 1.1 | |
Infused cells >2.7 (median)
|
0.04
|
0.7
|
0.6
|
1.0
| |
Nr mism >1 | 0.23 | 0.8 | 0.6 | 1.1 | |
OS | Female to male | 0.06 | 1.3 | 1.0 | 1.8 |
Age (years)
|
0.01
|
1.0
|
1.0
|
1.0
| |
Status at Tx
| |||||
CR1 versus CR2
|
<10–4
|
0.4
|
0.3
|
0.5
| |
CR1 versus advanced
|
0.01
|
0.6
|
0.4
|
0.9
| |
ATG | 0.23 | 1.2 | 0.9 | 1.7 | |
RIC | 0.35 | 0.8 | 0.6 | 1.2 | |
Sec AML | 0.35 | 0.8 | 0.6 | 1.2 | |
Infused cells >2.7 (median)
|
0.05
|
0.8
|
0.6
|
1.0
| |
Nr mism >1 | 0.40 | 0.9 | 0.7 | 1.2 |